Endocrine News and Research

RSS

Keryx Biopharmaceuticals initiates Phase 3 registration clinical trial for perifosine

Æterna Zentaris Inc., a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the initiation, by its partner Keryx Biopharmaceuticals Inc., of a Phase 3 registration clinical trial for perifosine (KRX-0401), the Company's PI3K/Akt pathway inhibitor, in relapsed/refractory multiple myeloma patients.

16 Dec 2009

Results from five new studies on Genomic Health's Oncotype DX breast cancer test announced

Genomic Health, Inc. today announced results from five new studies on its Oncotype DX® breast cancer test, a multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit and recurrence risk for patients with early-stage breast cancer.

16 Dec 2009

Health hazards of BPA: Call for FDA to make its announcement before Christmas

Environmental health advocates hope that U.S. FDA will make its promised announcement about health hazards of bisphenol A (BPA), a synthetic sex hormone linked to cancer, behavioral changes, reproductive harm and other illnesses, in time for Christmas.

15 Dec 2009

Researchers to receive more than $4.5 million in grants to study Sudden Infant Death Syndrome

Researchers at the Los Angeles Biomedical Research Institute (LA BioMed) expect to receive more than $4.5 million in grants from the American Recovery and Reinvestment Act (Recovery Act.), including nearly $1 million from the highly competitive Challenge Grant program for a study that seeks to reduce the number of children who die from Sudden Infant Death Syndrome, it was announced today.

15 Dec 2009

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

Breast cancer continues to be a dynamic field of research, and the CTRC-AACR San Antonio Breast Cancer Symposium, now in its 32nd year, is the premier destination to present new data on emerging therapies.

14 Dec 2009

Researchers present new data for diagnosis and management of beast cancer

As therapies for breast cancer continue to emerge, the issues of how to best monitor success and gauge prognosis remain important questions.

14 Dec 2009

Anti-estrogens may reduce the risk of death from lung cancer, according to study results

Anti-estrogens as therapy for breast cancer may also reduce the risk of death from lung cancer, according to study results presented at the CTRC-AACR San Antonio Breast Cancer Symposium, held here Dec. 9-13, 2009.

11 Dec 2009

National Health and Nutrition Examination Survey to be released by CDC

The National Health and Nutrition Examination Survey (NHANES) expected to be released today by the Centers for Disease Control (CDC) is on the right track with a focus on testing people's bodies for chemical contamination, say environmental health advocates working on chemical exposure issues.

11 Dec 2009

Winner of the 2010 Avanti Award in Lipids

The 2010 Avanti Award in Lipids, which recognizes outstanding research contributions in the area of lipid research, has been awarded to David W. Russell, the Eugene McDermott distinguished chair of molecular genetics at the University of Texas Southwestern Medical Center at Dallas.

11 Dec 2009

Social isolation and stress can raise breast cancer risk

Social isolation and related stress could contribute to human breast cancer susceptibility, research from a rat model designed at the University of Chicago to identify environmental mechanisms contributing to cancer risk shows.

8 Dec 2009

Study suggests sustained health risks linked to adverse childhood experiences

Research from the Institute of Psychiatry at King's College London has found that negative experiences in childhood may alter not only mental health but also physical health, into middle age and beyond.

8 Dec 2009

Cyntellect and Boston University sign research collaboration agreement

Cyntellect, Inc., a privately-held life sciences company commercializing products to advance life science and stem cell research, biopharmaceutical production, and drug discovery, today announced it has entered into a research collaboration agreement with the Boston University School of Medicine.

8 Dec 2009

Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.

7 Dec 2009

Study data of Perifosine + Bortezomib combination in multiple myeloma patients presented

Æterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner Keryx Biopharmaceuticals Inc. reported updated efficacy and safety data as well as new survival data on the clinical activity of perifosine (KRX-0401) in combination with bortezomib (Velcade(R)) (+/- dexamethasone) in patients with relapsed/refractory multiple myeloma.

7 Dec 2009

Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPH

Æterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.

7 Dec 2009

Anticoagulants used to prevent clots in placental blood vessels ineffective, reveals research

Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured. Sometimes, however, clots form on the inside of vessels without an obvious injury or do not dissolve naturally, a potentially life-threatening situation requiring treatment.

7 Dec 2009

Introduction of the Endocrine Disruption Prevention Act of 2009 commended

The Endocrine Society commends Representative Jim Moran (D-VA) and Senator John Kerry (D-MA) for introducing the Endocrine Disruption Prevention Act of 2009 (H.R. 4190; S. 2828). The bill, endorsed by the Society, amends the Public Health Service Act by authorizing the National Institute of Environmental Health Sciences to conduct a research program on endocrine disruption aimed at preventing and reducing the production of and the public's exposure to harmful chemicals.

5 Dec 2009

Rituximab drug may reduce long-term complications of type 1 diabetes

New findings by UT Southwestern researchers suggest that a drug already used to treat autoimmune disorders might also help slow the destruction of insulin-producing cells in patients recently diagnosed with insulin-dependent (type 1) diabetes.

4 Dec 2009

Pfizer to present study findings from its expanded breast cancer portfolio

Pfizer Oncology announced today that it will be presenting study findings evaluating several compounds including those from its newly expanded breast cancer portfolio following the recent acquisition of Wyeth, focusing on the needs of multiple breast cancer patient populations at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) being held December 9 – 13.

4 Dec 2009

FDA grants Fast Track designation for AEterna Zentaris' perifosine

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company's PI3K/Akt pathway inhibitor compound, perifosine (KRX-0401), for the treatment of relapsed/refractory multiple myeloma.

2 Dec 2009

Endocrine News and Research

Keryx Biopharmaceuticals initiates Phase 3 registration clinical trial for perifosine

Results from five new studies on Genomic Health's Oncotype DX breast cancer test announced

Health hazards of BPA: Call for FDA to make its announcement before Christmas

Researchers to receive more than $4.5 million in grants to study Sudden Infant Death Syndrome

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

Researchers present new data for diagnosis and management of beast cancer

Anti-estrogens may reduce the risk of death from lung cancer, according to study results

National Health and Nutrition Examination Survey to be released by CDC

Winner of the 2010 Avanti Award in Lipids

Social isolation and stress can raise breast cancer risk

Study suggests sustained health risks linked to adverse childhood experiences

Cyntellect and Boston University sign research collaboration agreement

Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported

Study data of Perifosine + Bortezomib combination in multiple myeloma patients presented

Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPH

Anticoagulants used to prevent clots in placental blood vessels ineffective, reveals research

Introduction of the Endocrine Disruption Prevention Act of 2009 commended

Rituximab drug may reduce long-term complications of type 1 diabetes

Pfizer to present study findings from its expanded breast cancer portfolio

FDA grants Fast Track designation for AEterna Zentaris' perifosine

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News